Table 2.
Summary of antigens targeted on different tumors by CAR-T cells in trials registered at clinicaltrials.gov.
| Organ | Cancer Type | Targeted Antigens |
|---|---|---|
| brain/CNS | brain | CD133, HER2, PSMA |
| glioma | B7-H3, CD147, EGFR, EGFRvIII, EphA2, GD2, HER2, IL13Rα2, MUC1, CD133 | |
| glioblastoma | B7-H3, ligands of chlorotoxin, EGFRvIII, HER2, IL13Rα2, NKG2D-Ligands, PD-L1 | |
| primitive neuroectodermal tumor | B7-H3 | |
| choroid plexus carcinoma | B7-H3 | |
| pineoblastoma | B7-H3 | |
| CNS tumor | B7-H3, EGFR806, HER2 | |
| ependymoma | B7-H3 | |
| medulloblastoma | B7-H3, NKG2D-Ligands | |
| several organs | rhabdoid tumor | B7-H3, EGFR, GPC3 |
| Rhabdomyosarcoma | B7-H3, EGFR, GPC3 | |
| desmoplastic small round cell tumor | B7-H3, EGFR | |
| sarcoma | GD2, HER2, NKG2D-Ligands, CD133, MUC1, CD117 | |
| adenocarcinoma | CEA | |
| solid tumors | B7-H3, CEA, claudin 18.2, EGFR, EGFR family member, GD2, GPC3, HER2, Lewis Y, mesothelin, MUC1, MUC16ecto, TnMuc1, Nectin4, ROR2 | |
| pancreas | pancreatic | CD70, CD133, CEA, claudin 18.2, EGFR, EpCAM, HER2, mesothelin, MUC1, Nectin4, NKG2D-Ligands, PSCA, ROR2, EGFRvIII |
| pancreatic ductal adenocarcinoma | claudin 18.2, mesothelin, TnMuc1 | |
| liver | liver | CD133, CEA, EGFR, EpCAM, GPC3, MG7, NKG2D-Ligands |
| HCC (hepatocellular carcinoma) | AFP/HLA-A2, CD147, GPC3, MUC1, NKG2D-Ligands, c-MET, PD-L1 | |
| hepatoblastoma | B7-H3, EGFR | |
| hepatoma | several | |
| gall bladder carcinoma | EGFR | |
| cholangiocarcinoma | EGFR, HER2, MUC1 | |
| lung | lung | CEA, EGFR, HER2, mesothelin, Lewis Y, PSCA, MUC1, PD-L1, CD80/86, MAGE-A1, MAGE-A4, GD2 |
| small cell lung cancer | DLL3 | |
| mesothelioma | FAP, mesothelin | |
| lung squamous cell carcinoma | GPC3 | |
| NSCLC | EGFR, mesothelin, MUC1, TnMuc1, Nectin4, PD-L1, ROR1, CD80/86 | |
| uterus/cervix | ovarian | CD70, CD133, CEA, EGFR, FBP, HER2, mesothelin, TnMuc1, Nectin4, NKG2D-Ligands |
| cervical | mesothelin, GD2, PSMA, MUC1, mesothelin | |
| fallopian tube | mesothelin, TnMuc1 | |
| breast | breast | CD44v6, CD70, CD133, CEA, c-MET, EpCAM, HER2, mesothelin, Muc1 (cleaved from), Nectin4, GD2 |
| TNBC | c-MET, mesothelin, MUC1, TnMuc1, NKG2D-Ligands, ROR1 | |
| colon | colorectal | CD133, CEA, EGFR, HER2, MUC1, NKG2D-Ligands |
| colon | EpCAM, HER2, NKG2D-Ligands | |
| kidney | renal | CD70, EGFR, VEGFR2, ROR2, AXL |
| neuroblastoma | B7-H3, CD171, EGFR, GD2, PSMA | |
| wilms tumor | B7-H3, EGFR, GPC3 | |
| stomach | gastric | CD44v6, CEA, claudin 18.2, EGFR, EpCAM, HER2, MUC1, NKG2D-Ligands, PSCA, ROR2 |
| prostate | prostate | CD44v6, EpCAM, NKG2D-Ligands, PSCA, PSMA |
| head/neck | esophageal | EpCAM, HER2, MUC1 |
| nasopharyngeal | EpCAM, LMP1, NKG2D-Ligands | |
| SCCHN | ErbB dimers, HER2 | |
| salivary gland | HER2 | |
| thyroid cancer | ICAM1 | |
| skin | melanoma | B7-H3, CD20, CD70, c-MET, GD2, gp100/HLA-A2, IL13Rα2, VEGFR2 |
| bladder | bladder | HER2, Nectin4, NKG2D-Ligands, ROR2, PSMA, FBP |
| soft tissue | synovial sarcoma | B7-H3, EGFR |
| clear cell sarcoma | B7-H3, EGFR | |
| soft tissue sarcoma | B7-H3, EGFR, GPC3, ROR2 | |
| bone | osteosarcoma | B7-H3, EGFR, GD2 |
| ewing sarcoma | B7-H3, EGFR | |
| abdomen | peritoneal | CEA, EpCAM, mesothelin |
| eye | retinoblastoma | B7-H3, EGFR |
| uveal melanoma | GD2 | |
| ovary/testis | germ cell tumor | B7-H3, EGFR, GPC3 |
| peripheral nerves | malignant peripheral nerve sheath tumor | B7-H3, EGFR |